Mental Health Demand Is Exploding. But Therapy Can't  Scale.

It's not the therapists. It's their delivery model.

TherAIpy scales human therapy. Without replacing it with a chatbot

The big issue with AI is that 99% of it is designed to replace the human. 

But mental health? That needs empathy and human connection. We believe you can't just strap on a chatbot and make noises about 'Human in the Loop'.

That's where TherAIpy comes in. We've figured out how to scale therapy while keeping it human: helping the millions of mental health professionals out there stay relevant and personal in an AI world.

23M

Existing therapists globally could be interested in buying

These people spent years on training and care about their clients. They want to keep that value. (Statista, 2023)

600%

Increase in productivity per therapist

Based on our tests.  Our system helps therapists work with more clients, and arguably offer them a better service too. 

99%

Reduction in effort

Our tests revealed that TherAIpy enables therapists to create personalized treatment plans in minutes—a process that previously took days or even months.

90%

Reduction in end prices 

We interviewed therapists and worked out that they could offer dramatically lower prices, yet still earn more revenue.



What is TherAIpy?

An AI and webtech platform that scales human therapy

TherAIpy is a UK Limited Company, based in the West of the UK.  We're SEIS approved and seeking early stage investment for a Proof of Concept.

We're reimagining therapy for the modern world—making it more affordable, more personalized, and giving therapists the tools to offer their clients more choices than ever before.

A Live Case Study

TherAIpy has a live prototype and is already testing the product commercially with some therapists. 

A World-Class Team With the Right Experience

There's very little risk with this team. These people know each other, some have worked together for 20 years.  They've all done this before. The whole here really is greater than the sum of the parts.

Simon 

Product Design

Simon is a lead UX, AI, product and content innovator, creator, and a therapist. 

Experience ranges from leading design on HSBC's flagship global AI product, to creating multi-award winning content at the BBC.

Gareth

Therapy Content

Gareth is one of the UK's most qualified and awarded therapists.

Clients include NHS, MIND, and qualifications include  MHFA, DCST, PDPCP, HPD, DSFH, DMH, AHD, MNCPS (Reg.) CNHC, NCTJ, MSC-CPA, PGCE

Dr. Scott

Lead AI

Scott is a PhD in AI voice in the wellness and medical sector.

He has the most perfect experience imaginable, having coded and built this requirement in previous MedTech roles.

Dr. Tory

Strategy Advisor

Tory ticks all those business boxes: Oxford, Harvard, MBA.

It just so happens she's an AI PhD, as well as a global strategy leader with companies such as BAIN and Diageo.

I can create a detailed, personalised treatment instantly, and the quality of the content and audio is just stellar, far higher than I could do myself. 

Einir
Therapist

SEIS investment creates an 18 month runway

The initial SEIS investment ask focuses on providing the next level of key AI technology, and driving revenue. 

A future-proof AI and human hybrid?

TherAIpy doesn't use an LLM.

An AI business not piggybacking on OpenAI? Exactly. 

We have a unique IP that is very, very different to normal AI startups. Let's just call it more human for now.

Not just an idea

Despite being an early-stage SEIS project, TherAIpy is already testing with therapists. Our lead example: 'Serenity,' is a complex menopause therapy course for women.

Contact us

E-mail: simon@theraipy.co.uk

TherAIpy Limited is a UK Limited Company based in Bath, England.

Important disclaimer

TherAIpy Limited has been approved by HMRC under the Seed Enterprise Investment Scheme (SEIS). 

This means the company itself meets the qualifying conditions for SEIS investment. However, an investor’s ability to claim SEIS tax relief depends on their own circumstances and on HMRC’s final assessment of their investment. 

Investing in early-stage companies involves significant risks, including potential loss of all invested capital and lack of liquidity. Nothing on this website constitutes financial, tax, or legal advice. Investors should obtain independent professional advice before investing.

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.